Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Opposes Seizure Of Drugs By EU Even As Dr. Reddy’s Labs Brings Its Goods Back

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Stung by strictures on Indian companies routing drug consignments through the European Union, the Indian government is considering drastic measures in a bid to control further damage to India's pharmaceutical trade

You may also be interested in...



Challenges To The Indian Drug Industry Subtle, Manifold and More Potent Now, Pharma Lobby Tells Government

MUMBAI - A spate of adverse moves by developed countries and international agencies in the past year have been most challenging for the Indian drug industry, says the Indian Pharmaceutical Alliance - the lobby of top Indian generic drug makers

Challenges To The Indian Drug Industry Subtle, Manifold and More Potent Now, Pharma Lobby Tells Government

MUMBAI - A spate of adverse moves by developed countries and international agencies in the past year have been most challenging for the Indian drug industry, says the Indian Pharmaceutical Alliance - the lobby of top Indian generic drug makers

Faced With Trade Barriers, Indian Government Forms Committee To Charter Progress Of Indian Pharmaceutical Exports

NEW DELHI - In another of its spirited attempts to make India a major exporter of pharmaceutical products, the Indian government has formed a joint working group with members from the Department of Pharmaceuticals and Ministry of Commerce, among others

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel